Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript

Sabirnetug topline results expected November 2026 for early Alzheimer's disease trial.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at fool.com →

More in Finance & Markets

XLU, PSCI: Big ETF Outflows

Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the State Street Utilities Select Sector SPDR ETF, where…

S&P 500 Analyst Moves: ROST

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Ross Stores is now the #46 analyst pick, moving up by 6 spots.

More from Monday 26 October →